BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

AIMS Molecular Science is a premier open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to the advancement and dissemination of high-quality research in the field of molecular science. Since its inception in 2014, this journal has established itself as a vital platform for researchers and professionals aiming to share their findings in molecular biology, chemistry, and interdisciplinary studies related to these domains. With an increasing focus on the accessibility of scientific knowledge, AIMS Molecular Science supports the open-access movement, ensuring that all published articles are freely available to the global research community. The journal emphasizes originality and significance in research, promoting innovative scientific methodologies and applications. By fostering collaboration and dialogue among scientists, AIMS Molecular Science plays a crucial role in advancing understanding and stimulating progress in molecular sciences.

Current Cancer Therapy Reviews, an esteemed journal published by Bentham Science Publishers Ltd, serves as a critical resource in the fields of cancer research, molecular medicine, and oncology. With an ISSN of 1573-3947 and an E-ISSN of 1875-6301, this journal provides a platform for the rapid dissemination of reviews that articulate the latest advancements and therapeutic strategies in cancer treatment. Although it currently holds a Q4 classification in its respective categories, the journal's commitment to quality scholarship is evident in its engagement with an expansive range of topics impacting cancer care. Operating from the United Arab Emirates since its inception in 2006, it is an essential tool for researchers, clinicians, and students aiming to stay abreast of the evolving landscape of cancer therapy. The journal emphasizes open access to knowledge, fostering a collaborative environment for innovative research. For those looking to deepen their understanding of contemporary cancer therapies, Current Cancer Therapy Reviews is a valuable addition to their academic resources.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.

Cell and Bioscience is a prestigious open-access journal published by BMC that has been at the forefront of biochemistry, genetics, and molecular biology since its inception in 2011. With an impressive impact factor, this journal has established itself as a vital resource for researchers and professionals in these rapidly advancing fields, reflecting its high ranking of #29 out of 221 in the Scopus classification and placing it in the 87th percentile. Based in the United Kingdom, Cell and Bioscience aims to foster innovation and dissemination of research findings addressing critical biological questions through rigorous peer-reviewed articles and inter-disciplinary approaches. The journal's open-access model ensures unrestricted access to transformative research, promoting collaboration and knowledge sharing among academics, students, and practitioners worldwide. With a commitment to maintaining excellence in the field, Cell and Bioscience provides an essential platform for those looking to contribute to the evolving landscape of biosciences.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.